Tag Archive for: drug prices

MBTAAnalysis: A look inside the MBTA

0 Comments
/
The MBTA shuttles over a million passengers a day around Greater…

The Clock is Ticking…….

0 Comments
/
The clock is ticking towards December 30, 2017.  As part of…

Drug Price Control: Bad Medicine for Healthcare and Region

Hubwonk host Joe Selvaggi talks with Dr. Bill Smith, Director of Pioneer Institute’s Life Sciences Initiative, about the impact of the Inflation Reduction Act on long-term health costs. They discuss the bill's unintended consequences, potential effect on the region’s vibrant pharmaceutical research and development sector, and what citizens can do about it.

Drug Cost Disruption: Direct Generic Access Can Save Consumers Billions

Hubwonk host Joe Selvaggi talks with Dr. Hussain Lalani about his recently published research on the potential for more than $3 billion in savings were Medicare to use Mark Cuban’s new direct-to-consumer drug company to purchase generics.

Pharmacy Benefit Profiteers: Distortions and Costs of Half-Trillion Dollar Drug Middlemen

Hubwonk Host Joe Selvaggi talks with ALVA10 Chief Executive Hannah Mamuszka and Dr. Blake Long about the perverse incentives imposed by Pharmacy Benefit Managers adding nearly $500 billion to U.S. drug costs.

Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes

Over the past decade, the revenue for hospitals generated by the federal 340B drug discount program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide, according to a new study published by Pioneer Institute. The Pioneer Institute study, “340B Drug Discounts: An Increasingly Dysfunctional Program,” notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

340B Drug Discounts: An Increasingly Dysfunctional Program

This report reviews the federal 340B drug discount program, showing that, over the past decade, the revenue for hospitals generated by the program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide. The study notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

Valuing Life-Saving Drugs: What is the Price of Life and Who Decides?

Hubwonk host Joe Selvaggi talks with Pioneer Institute visiting fellow Dr. Bill Smith about Quality Adjusted Life Years (QALY) standards, and the ways in which so-called objective cost-containing strategies use expert opinion to determine the value of a life and thereby disadvantage the elderly, disabled, and those with less common vulnerabilities to disease.

Drug Rebates: How Pharmacy Benefit Managers Manipulate Price & Limit Choice

0 Comments
/
Join host Joe Selvaggi and his guest Dr. Bill Smith as they discuss the complex incentive structure between drug manufacturers, health plans, and pharmacy benefit managers. In this episode, they focus on how drug rebates work and how a system intended to optimize value may actually deliver higher costs and fewer choices. Joe and Bill also use this framework to speculate on the price of a COVID-19 vaccine, and who will likely pay for it.

Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.

Five Reasons Why Drug Rebates Are Harmful to Patients and to the Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.